IL18 and conjunctival squamous cell carcinoma: Because cis-UCA can inhibit the secretion of IL-1β and IL-18 along with its cytoprotective and therapeutic effects, it may well find extensive applications in several pathological conditions (e.g., pterygium, photokeratitis, CDK, and ocular surface squamous neoplasia where UV-B causes cell damage and inflammation).3